Suggested remit: To appraise the clinical and cost effectiveness of remibrutinib within its marketing authorisation for treating chronic spontaneous urticaria that is inadequately controlled by H1-antihistamines.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6356
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 July 2025 - 04 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6356 |
| 07 July 2025 | In progress. Scoping commenced. |
| 13 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual